Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, Imazeki K, Nakajima N
First Department of Surgery, Chiba University School of Medicine, Japan.
Cancer. 1998 Jun 1;82(11):2227-34.
Positron emission tomography (PET) with 2-deoxy-2-fluoro[18F]-D-glucose (FDG) can provide quantitative information about tumor glucose metabolism. The prognostic value of this technique was evaluated for breast carcinoma patients.
FDG PET was performed on 70 patients with primary breast carcinoma, and the differential absorption ratio (DAR) was calculated as an index of FDG uptake. Overall and relapse free survival curves were created by the Kaplan-Meier method, and differences between the curves were analyzed with the log rank test. For multivariate analysis, the Cox proportional hazards regression model was used.
The mean DAR was 2.61+/-1.61 standard deviation (range, 0.65-9.39). According to the grade of DAR, patients were then classified into high DAR (> or =3.0) and low DAR (<3.0) groups. The high DAR group had significantly worse prognoses for both overall and relapse free survival (P < 0.0005 and P < 0.0001, respectively). In multivariate analysis, DAR was an independent predictor of the relapse free survival of breast carcinoma patients (P=0.0377).
DAR, as determined by FDG PET, may be useful as a prognostic indicator for patients with primary breast carcinoma.
采用2-脱氧-2-氟[18F]-D-葡萄糖（FDG）的正电子发射断层扫描（PET）可提供有关肿瘤葡萄糖代谢的定量信息。对乳腺癌患者评估了该技术的预后价值。
对70例原发性乳腺癌患者进行FDG PET检查，并计算差异吸收率（DAR）作为FDG摄取指标。采用Kaplan-Meier法绘制总生存曲线和无复发生存曲线，并用对数秩检验分析曲线间差异。多因素分析采用Cox比例风险回归模型。
平均DAR为2.61±1.61标准差（范围0.65 - 9.39）。根据DAR分级，患者随后被分为高DAR（≥3.0）和低DAR（<3.0）组。高DAR组的总生存和无复发生存预后均显著较差（分别为P < 0.0005和P < 0.0001）。多因素分析中，DAR是乳腺癌患者无复发生存的独立预测因素（P = 0.0377）。
FDG PET测定的DAR可能作为原发性乳腺癌患者的预后指标。
